{"preliminary_commentary":{"by_channel":{"podcast":3,"x_thread":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06966700\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"TroFuse-032","nct_id":"NCT06966700","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trofuse-032-nct06966700. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive sacituzumab tirumotecan intravenously (IV) at a dose of 4 mg/kg every 2 weeks (Q2W) + IV pembrolizumab 200 mg every 3 weeks (Q3W), for 12 weeks; then receive IV pembrolizumab 200 mg Q3W and IV carboplatin area under the curve (AUC) 1.5 + IV paclitaxel 80 mg/m\\^2 once weekly, for 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant treatment of physician's choice (TPC) may be administered to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); capecitabine 1000-1250 mg/m\\^2 oral twice daily on days 1-14 and 22-35 each cycle for 4 six-week cycles; or doxorubicin 60mg/m\\^2 (or epirubicin 90 mg/m\\^2) IV infusion Q3W/Q2W + cyclophosphamide 600 mg/m\\^2 IV infusion Q3W/Q2W for 4 doses.","label":"sac-TMT","type":"EXPERIMENTAL"},{"description":"Participants receive IV carboplatin AUC 1.5 and paclitaxel 80 mg/m\\^2 once weekly, alongside pembrolizumab 200 mg Q3W, for 6 weeks; then receive IV pembrolizumab 200 mg Q3W alongside IV cyclophosphamide 600 mg/m\\^2 Q3W and either doxorubicin 60 mg/m\\^2 Q3W or epirubicin 90 mg/m\\^2 Q3W, for up to 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options are olaparib 300 mg oral BID for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); or capecitabine 1000-1250 mg/m\\^2 oral BID on days 1-14 and 22-35 each cycle for 4 six-week cycles.","label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2034-12-29","type":"ESTIMATED"},"conditions":["Breast Neoplasms","Triple Negative Breast Neoplasms","HR Low-Positive/HER2-Negative Breast Neoplasms"],"enrollment":{"count":2400,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab tirumotecan","otherNames":["Sac-TMT","MK-2870"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":["MK-3475","Keytruda®"],"type":"BIOLOGICAL"},{"name":"Rescue Medication","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Paraplatin"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Taxol","Onxol"],"type":"DRUG"},{"name":"Doxorubicin","otherNames":["ADRIAMYCIN®"],"type":"DRUG"},{"name":"Epirubicin","otherNames":["Ellence®"],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":["Cytophosphane"],"type":"DRUG"},{"name":"Capecitabine","otherNames":["Xeloda®"],"type":"DRUG"},{"name":"Olaparib","otherNames":["LYNPARZA®"],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2033-03-23","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery","timeFrame":"Up to approximately 30 weeks"},{"measure":"Event-Free Survival (EFS)","timeFrame":"Up to approximately 92 months"}],"references":[{"citation":"Schmid P, Cortes J, Hui R, Masuda N, Garrido-Castro AC, Loirat D, Shao ZM, Park YH, Wei J, Beca F, Malhotra U, Harbeck N. TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer. Future Oncol. 2026 Oct 14:1-11. doi: 10.1080/14796694.2026.2732590. Online ahead of print.","pmid":"42872715","type":"DERIVED"}],"start_date":{"date":"2025-06-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","url":"https://clinicaltrials.gov/study/NCT06966700"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trofuse-032-nct06966700"}